Digna Cespedes-Cloud
Psychiatric/Mental Health · Baltimore, MDNPI 1457826133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,452, 5.8 times the $420 reported in 2021. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $68.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$917
- AbbVie$916
- Novo Nordisk$608
- E.r. Squibb & Sons, L.L.C.$531
- Teva Pharmaceuticals USA, Inc.$514
- Sanofi-aventis U.S. LLC$309
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,40098%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $917 |
| AbbVie | 22 | $916 |
| Novo Nordisk | 5 | $608 |
| E.r. Squibb & Sons, L.L.C. | 9 | $531 |
| Teva Pharmaceuticals USA, Inc. | 7 | $514 |
| Sanofi-aventis U.S. LLC | 3 | $309 |
| Johnson & Johnson(2 entities) | 2 | $227 |
| Alkermes, Inc. | 5 | $217 |
| Idorsia Pharmaceuticals US Inc | 2 | $211 |
| Biogen | 2 | $193 |
| Neurocrine Biosciences, Inc. | 5 | $178 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $168 |
| Vertex | 2 | $167 |
| Vanda Pharmaceuticals Inc. | 3 | $160 |
| Axsome Therapeutics, Inc. | 2 | $144 |
| Boston Scientific | 1 | $138 |
| Indivior Inc. | 6 | $131 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| Bristol Myers Squibb | 1 | $124 |
| Dexcom, Inc. | 1 | $121 |
| Amarin Pharma, Inc. | 1 | $120 |
| Aimmune Therapeutics, Inc. | 1 | $120 |
| Hologic Sales And Service, LLC | 1 | $119 |
| EMD Serono, Inc. | 1 | $116 |
| Sanofi Pasteur Inc. | 1 | $107 |
| Bayer | 1 | $107 |
| Sage Therapeutics, LLC | 1 | $99 |
| Madrigal Pharmaceuticals | 1 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $82 |
| Coloplast | 1 | $76 |
| Insmed, Inc. | 1 | $72 |
| Solventum Corporation | 1 | $47 |
| TMS Neurohealth Centers Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,518 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Baltimore
- Olalekan AjayiBaltimore$10K
- Amy GrammasBaltimore$8K
- Nalo FordBaltimore$8K
- Gerald ChiaBaltimore$6K
- Chinwe OkudoBaltimore$6K
- Tamar RodneyBaltimore$6K
- Peter IgeBaltimore$5K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.